Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Obesity is a key therapeutic area for Pfizer, and the company has a robust pipeline of three clinical and several pre-clinical candidates
Every milestone is acknowledged, which creates positive momentum and reinforces commitment
Despite this, the peptide gained significant attention in research communities studying growth hormone modulation and anti-aging applications
Fits weight management, metabolism, and wellness categories
Si consideras compuestos por costo, habla con tu clnico
Retatrutide, Lillys follow-on molecule, is a triple agonist that adds the glucagon receptor to the same dual backbone and, in its first Phase 3 readout, produced the deepest weight reduction ever reported in a registrational obesity trial: about 28.7% at 68 weeks 5 vs tirzepatides SURMOUNT-1 peak of roughly 22.5% at 72 weeks 13
US$ 27.92
US$ 22.24
US$ 20.67
US$ 21.74
US$ 28.21
